Sugi Predict

Sugi Predict / Compounds / SCHEMBL1637575

SCHEMBL1637575

SCHEMBL1637575

O=C(NN=Cc1c(O)ccc2ccccc12)c1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RRM1 P23921 5/20 1.00
▸ IDO1 P14902 2/20 0.74
▸ MEN1 O00255 7/20 0.70
▸ KMT2A Q03164 7/20 0.70
▸ NPC1 O15118 6/20 0.70
▸ RAB9A P51151 6/20 0.69
▸ PPARG P37231 1/20 0.68
▸ PAX8 Q06710 1/20 0.67
▸ KLF5 Q13887 3/20 0.63
▸ POLB P06746 2/20 0.63
▸ TDP1 Q9NUW8 1/20 0.63
▸ MITF O75030 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ L3MBTL1 Q9Y468 1/20 0.63
▸ KDM4E B2RXH2 1/20 0.61
▸ GLA P06280 1/20 0.61
▸ MAPT P10636 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29366011 1.00 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL4454258 1.00 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL1637574 1.00 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL18963239 0.88 RRM1 (1.00) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL1639477 0.87 RRM1 (0.77) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL1639479 0.87 RRM1 (0.77) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL12766750 0.87 RRM1 (0.77) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL683715 0.85 MEN1 (0.85) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL2847708 0.85 MEN1 (0.85) RRM1IDO1MEN1KMT2ANPC1
SCHEMBL7602938 0.84 RRM1 (0.72) RRM1IDO1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962677-B2 Methods of restoring cognitive ability using non-peptidic compounds ACUMEN PHARMACEUTICALS, INC. (US) 2015-02-24 — — US claimed
EP-2173340-B1 METHODS OF ENHANCING COGNITIVE FUNCTION USING NON-PEPTIDIC COMPOUNDS ACUMEN PHARMACEUTICALS INC (US) 2013-07-10 — — EP claimed
US-12011432-B2 Method of modulating ribonucleotide reductase CASE WESTERN RESERVE UNIVERSITY (US) 2024-06-18 — — US disclosed
US-20210299095-A1 METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE CASE WESTERN RESERVE UNIVERSITY 2021-09-30 — — US disclosed
US-20180360782-A1 METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE UNIV CASE WESTERN RESERVE (US) 2018-12-20 — — US disclosed
EP-3377053-A1 METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE Case Western Reserve University (US) 2018-09-26 — — EP disclosed
WO-2017100644-A1 METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE CASE WESTERN RESERVE UNIVERSITY (US) 2017-06-15 — — WO disclosed
US-20150320860-A1 METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 MERCK SHARP AND DOHME CORP. 2015-11-12 — — US disclosed
CN-103664685-B 3,3 '-bis-(2-hydroxyl-1-naphthylamino azo-group)-4,4 '-'-biphenyl diphenol and its preparation method and application SHANXI DATONG UNIVERSITY (CN) 2015-10-28 — — CN disclosed
US-8962677-B2 Methods of restoring cognitive ability using non-peptidic compounds ACUMEN PHARMACEUTICALS, INC. (US) 2015-02-24 — — US disclosed
EP-2173340-B1 METHODS OF ENHANCING COGNITIVE FUNCTION USING NON-PEPTIDIC COMPOUNDS ACUMEN PHARMACEUTICALS INC (US) 2013-07-10 — — EP disclosed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 — — US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 — — EP disclosed
US-20090018084-A1 METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS ACUMEN PHARMACEUTICALS, INC. 2009-01-15 — — US disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018084-A1 METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS BCHE, APP, ACHE RRM1 3967/4885IDO1 2004/4885MEN1 2353/4885
US-20210299095-A1 METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE RRM2, RRM2B, RRM1 RRM1 3/4885IDO1 2335/4885MEN1 3447/4885
US-20180360782-A1 METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE RRM2, RRM2B, RRM1 RRM1 3/4885IDO1 3024/4885MEN1 3193/4885
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 RRM1 3099/4885IDO1 1981/4885MEN1 2974/4885
US-12011432-B2 Method of modulating ribonucleotide reductase RRM2, RRM2B, RRM1 RRM1 3/4885IDO1 2335/4885MEN1 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.